Company intelligence / Profile preview

Synthesize Bio

Seattle, Washington, United Statessynthesize.bio ↗

Ownership: Private
Employees: ~17
Development stage: Other

Overview

Synthesize Bio has developed an AI-powered platform that accelerates the generation, analysis, and hypothesis testing of genomic data. The technology allows researchers to generate synthetic gene expression datasets in minutes instead of months, combine them with experimental or public data, and perform advanced analyses such as differential expression. The company’s tools are designed to support basic research through therapeutic development but does not itself have clinical programs or results.

Industry: Drug Discovery Services

Partnerships

No major pharma/biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Synthesize Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthesize Bio.

Explore the full profile